Tag Archives: MURAL spinoff

Mural Oncology Paints Itself Into A Corner After Nemvaleukin Alfa Fails

By |
1 Comment
mural oncology wind down

  In November 2023, Alkermes plc (ALKS) spun off its oncology division into a new company: Mural Oncology plc (MURA). Armed with $275 million in cash, no debt, and a clean slate, the company was designed as a single-focus biotech aimed at bringing nemvaleukin alfa, an engineered IL-2 cytokine, through late-stage development. Less than two years later, the… Read More »

Painting a Beautiful Mural: Alkermes Completes Spinoff Of Mural Oncology

By |
0 Comment

With a goal of becoming “a pure-play, profitable neuroscience company”, on November 15, Alkermes(ALKS) spun off its oncology business as Mural Oncology(MURA). In the tax free spinoff, Alkermes shareholders as of November 6 received one share of Mural for every ten shares owned. According to BioPharma Dive, the $275 million in cash that Mural has to start with… Read More »